TOMZ

TOMI Environmental Solutions, Inc. (TOMZ) - 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended September 30, 2025. TOMI Environmental Solutions, Inc. is a global provider of disinfection and decontamination essentials using its Binary Ionization Technology (BIT) platform, primarily under the SteraMist brand. The company operates in four divisions: Life Sciences, Hospital Healthcare, Food Safety, and Commercial. The filing identifies the company as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Q3 2025 revenue decreased 21% year-over-year (YoY) to $2.01 million, and YTD revenue decreased 31% to $4.62 million. Management attributes this to timing reductions in service sales due to a key customer restructuring and delayed capital investment decisions by customers facing tariff uncertainty.
• Profitability Shift: The company reported a net loss of $450,348 in Q3 2025, compared to a net income of $58,962 in Q3 2024. The YTD 2025 net loss of $1.94 million widened from $1.22 million in the prior year.
• Expense Management: Operating expenses increased 10% in Q3 2025 compared to Q3 2024, driven primarily by higher professional fees (audit, legal, compliance) and credit loss expenses, partially offset by reduced selling and R&D expenses.
• Unusual Items: YTD 2025 results included $534,912 in "Other Income" from Employee Retention Credits (ERC) refunds, which significantly mitigated the YTD net loss. Without this one-time benefit, the loss would have been substantially higher.
• Liquidity: Cash and cash equivalents decreased from $664,879 at year-end 2024 to $490,022 at September 30, 2025. However, cash used in operating activities improved significantly YoY (from $1.45M to $0.58M) due to better working capital management.

Guidance, Outlook, and Risks

• Going Concern: The filing explicitly states that the company's accumulated deficit of $56.2 million and net losses raise substantial doubt about its ability to continue as a going concern within one year. Management plans to fund operations through existing cash, operational cash flow, and additional equity or debt financing.
• Capital Raising: On November 5, 2025 (subsequent event), the company entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC, allowing the sale of up to $20 million of common stock over 24 months. Additionally, $535,000 in convertible notes were issued during the quarter.
• Market Outlook: Management highlights a strong pipeline with a sales order backlog of $1.3 million as of October 31, 2025, and negotiations for an additional $2-3 million in contracts. Growth is expected in Life Sciences and Food Safety sectors, bolstered by new FDA rules permitting hydrogen peroxide use on food contact surfaces.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting due to limited resources in the finance department and ineffective review procedures. A new CFO was appointed in May 2025 to assist with remediation.
• Risks: Key risks include customer concentration (one customer represented 23% of Q3 revenue), reliance on a single product line, and the uncertainty of raising additional capital on acceptable terms.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $490k cash balance against monthly burn rates given the "substantial doubt" going concern warning.
• Debt Obligations: Review the terms of the $2.9M in convertible notes (12% interest, conversion price $1.25) and the potential dilution from the new $20M equity facility.
• Revenue Quality: Assess the sustainability of revenue given the 21% Q3 decline and the heavy reliance on a single customer (23% of Q3 sales).
• One-Time Gains: Adjust financial analysis to exclude the $535k ERC tax credit to understand core operational performance.
• Internal Controls: Monitor the progress of remediation plans for the disclosed material weakness in financial reporting.